Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2021

View Archived Issues

S1P levels found to be tied to clinical severity of COVID-19 disease

Liver metastases are immunosuppressive

ChAdOx1 nCoV-19 vaccine shows lower reactogenicity profile in older adults than in younger adults

Phase I results for talimogene laherparepvec as addition to NAC in TNBC

REGN-COV2 shows greater efficacy in COVID-19 patients with high viral load at baseline

Wistar Institute patents ACSS2 inhibitors

The Vanderbilt University synthesizes new compounds for cancer

Dana-Farber Cancer Institute presents new HDAC3 inhibitors

IHMT-TRK-284 shows efficacy in models of TRK kinase fusion or mutant-driven cancers

JS Innopharm (Shanghai) identifies RET and/or VEGFR-2 inhibitors

Platelets boost stem cell function through mitochondrial donation

New ISR pathway inhibitors presented by Praxis Biotech

Killing Mycobacterium tuberculosis, some assembly required

Imara reports phase IIa data on IMR-687 in sickle cell disease

E.U. conditional marketing authorization for Moderna's COVID-19 vaccine

Kyowa Kirin opens phase III study of bardoxolone methyl for ADPKD in Japan

Endpoints met in phase Ib/II trial of BXCL-501 for agitation in dementia

Phase III trial of sacituzumab govitecan in metastatic urothelial cancer cleared to begin in China

Windtree initiates phase II trial of lucinactant for COVID-19-associated acute lung injury

FDA lifts partial clinical hold on Marker's phase II trial of MT-401 for AML

Chemomab reports phase Ib data on CM-101 in patients with NAFLD

Treatment begins in phase I/IIa trial of AXT-107 in DME

FDA allows Cure's IND for CUREfilm Blue

Inovio reports phase II data on VGX-3100 to treat HPV-16- and -18-associated vulvar dysplasia

Phase III ultraVIOLET study of oteseconazole for recurrent VVC meets endpoints

Cerecor reports phase II proof-of-concept data for CERC-002 in COVID-19 ARDS